12:00 AM
May 11, 2009
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Heplisav: Additional Phase III data

Additional data from the single-blind, international Phase III PHAST trial in 2,428 patients showed that there was a significant difference in the seroprotection rate between patients receiving Heplisav and Engerix-B HBV vaccine at each time point: 24% vs. 4% at month 1; 89% vs. 26% at month...

Read the full 224 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >